Dmitry Balyasny’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-70,485
| Closed | -$2.65M | – | 2640 |
|
|
2021
Q1 | $2.65M | Buy |
+70,485
| New | +$1.76M | 0.01% | 931 |
|
|
2018
Q3 | – | Sell |
-34,268
| Closed | -$542K | – | 2183 |
|
|
2018
Q2 | $542K | Sell |
34,268
-156,971
| -82% | -$2.74M | ﹤0.01% | 1328 |
|
|
2018
Q1 | $3.29M | Sell |
191,239
-258,911
| -58% | -$5.05M | 0.01% | 831 |
|
|
2017
Q4 | $9.87M | Buy |
+450,150
| New | +$14.5M | 0.03% | 651 |
|
|
2017
Q2 | – | Sell |
-83,289
| Closed | -$3.01M | – | 1865 |
|
|
2017
Q1 | $3.01M | Sell |
83,289
-88,062
| -51% | -$3.88M | 0.01% | 814 |
|
|
2016
Q4 | $8.59M | Buy |
171,351
+111,351
| +186% | +$5.85M | 0.05% | 528 |
|
|
2016
Q3 | $3.15M | Sell |
60,000
-91,996
| -61% | -$4.39M | 0.02% | 573 |
|
|
2016
Q2 | $6.29M | Buy |
151,996
+51,746
| +52% | +$2.25M | 0.04% | 461 |
|
|
2016
Q1 | $4.07M | Sell |
100,250
-125,552
| -56% | -$4.32M | 0.02% | 585 |
|
|
2015
Q4 | $9.37M | Sell |
225,802
-110,365
| -33% | -$3.7M | 0.07% | 382 |
|
|
2015
Q3 | $5.17M | Buy |
+336,167
| New | +$7.22M | 0.04% | 516 |
|
Dmitry Balyasny's FPRX Position: Q2 2021 in Review
Dmitry Balyasny sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 70,485 shares — an estimated $2.65M sold.
Dmitry Balyasny first reported a position in FPRX in Q3 2015 and held it in 11 quarters. The position peaked at $9.87M in Q4 2017. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Dmitry Balyasny reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Dmitry Balyasny sold 70,485 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $2.65M.
- Dmitry Balyasny first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 11 quarters.
- Dmitry Balyasny's Five Prime Therapeutics, Inc. position peaked at $9.87M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Balyasny Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.